RHEUMATOID ARTHRITIS · White paper
Rheumatoid Arthritis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About rheumatoid arthritis — and why its trials are hard
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease in which the immune system attacks the synovium, producing symmetric polyarthritis, joint destruction, and extra-articular complications. Diagnosis and trial enrolment rest on the 2010 ACR/EULAR scoring criteria incorporating joint involvement, serology (RF/ACPA), acute-phase reactants, and symptom duration. Treatment evolved from conventional synthetic DMARDs - with methotrexate remaining the anchor - to biologic DMARDs (TNF inhibitors adalimumab, etanercept, infliximab; the IL-6 receptor antagonist tocilizumab; the T-cell costimulation blocker abatacept; and the B-cell agent rituximab) and targeted synthetic JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Efficacy endpoints are dominated by ACR20/50/70 response, DAS28 remission, radiographic progression (Sharp/van der Heijde), and patient-reported outcomes like the HAQ. Safety is a defining theme: the post-marketing ORAL Surveillance trial of tofacitinib flagged increased major adverse cardiovascular events and malignancy versus TNF inhibitors, reshaping JAK-inhibitor labeling and reinforcing the need for long-term safety monitoring, thromboembolism vigilance, and robust pharmacovigilance.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Methotrexate (Generic (Rheumatrex/Trexall)) | 1988 | First-line conventional synthetic DMARD for RA | MIRA; COBRA | ACR response; radiographic progression | Significant symptom reduction and slowed joint damage; established as anchor DMARD |
| Etanercept (Enbrel) | 1998 | RA (TNF-alpha inhibitor), mono or with MTX | TEMPO; ERA | ACR20/50/70; Sharp score | TEMPO: ACR20 ~77% with etanercept+MTX vs ~59% etanercept alone; reduced radiographic progression |
| Adalimumab (Humira) | 2002 | RA (TNF-alpha inhibitor), mono or with MTX | ARMADA; DE019; STAR | ACR20/50/70; Sharp score; HAQ-DI | ACR20 up to 63% (HUMIRA/MTX) vs 30% placebo/MTX at 24 wks; less radiographic damage |
| Abatacept (Orencia) | 2005 | RA (T-cell costimulation modulator) | AIM; ATTAIN | ACR20/50/70; HAQ; radiographic progression | Improved ACR responses and physical function in MTX- and anti-TNF-inadequate responders |
| Tocilizumab (Actemra) | 2010 | RA (IL-6 receptor antagonist) | LITHE; OPTION; AMBITION | ACR20/50/70; DAS28 remission; Sharp-Genant | e.g., ACR20 ~70% vs 53% MTX (Week 24); DAS28<2.6 ~32% (8 mg/kg) vs 3% placebo |
| Tofacitinib (Xeljanz) | 2012 | RA (oral JAK inhibitor), refractory cases | ORAL program (ORAL Standard/Scan/Solo) | ACR20/50/70; DAS28; HAQ-DI | Significant ACR/DAS28 improvement vs placebo; note ORAL Surveillance MACE/malignancy safety signal vs TNFi |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in rheumatoid arthritis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Fostamatinib — NCT01264770 | Development for RA discontinued; rights returned to Rigel | Sponsor (AstraZeneca) decision amid efficacy/tolerability profile for RA indication |
| Sirukumab — NCT01856309 | Anti-IL-6 program did not advance in RA | Safety findings including mortality imbalance dampened benefit-risk despite efficacy |
| Tregalizumab — NCT01999192 | Lack of efficacy in achieving primary endpoints | CD4-targeting mechanism failed to demonstrate clinical benefit |
Choosing the right endpoint
Primary endpoints that matter in rheumatoid arthritis trials
- ACR20 / ACR50 / ACR70 — Percentage of patients with 20/50/70% improvement in tender/swollen joints plus core measures; ACR20 is common but may understate benefit in severe disease
- DAS28 — Composite Disease Activity Score over 28 joints with ESR or CRP; DAS28-CRP preferred for specificity; <2.6 denotes remission
- Radiographic progression (Sharp/van der Heijde) — Structural joint-damage endpoint scored on X-ray; slow to change and reader-dependent, so blinded central reading is used
- Patient-Reported Outcomes (HAQ-DI, VAS) — Capture function, pain, and quality of life; subjective, so standardized validated instruments improve reliability
- Clinical remission / safety endpoints — ACR/EULAR Boolean or SDAI remission as the treatment goal; long-term safety monitoring is essential given infection, malignancy, CV, and thromboembolic risks
How iNGENū runs rheumatoid arthritis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Rheumatoid Arthritis clinical trials — FAQs
What are the standard efficacy endpoints in RA trials?
How does RA treatment escalate across drug classes?
What is the safety concern with JAK inhibitors in RA?
Ready to discuss your rheumatoid arthritis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal